Journal article
Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States
Abstract
BACKGROUND: Targeted therapies (TTs) have revolutionized metastatic renal cell carcinoma (mRCC) treatment in the past decade, largely replacing immunotherapy including high-dose interleukin-2 (HD IL-2) therapy. We evaluated trends in HD IL-2 use for mRCC in the TT era.
METHODS: Our cohort comprised a weighted estimate of all patients undergoing HD IL-2 treatment for mRCC from 2004 to 2012 using the Premier Hospital Database. We assessed …
Authors
Allard CB; Gelpi-Hammerschmidt F; Harshman LC; Choueiri TK; Faiena I; Modi P; Chung BI; Tinay I; Singer EA; Chang SL
Journal
Urologic Oncology Seminars and Original Investigations, Vol. 33, No. 11, pp. 496.e11–496.e16
Publisher
Elsevier
Publication Date
November 2015
DOI
10.1016/j.urolonc.2015.06.014
ISSN
1078-1439